MedPath

成都恒瑞制药有限公司

Ownership
-
Established
2001-03-07
Employees
-
Market Cap
-
Website
http://www.santao.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

49

NMPA:49

Drug Approvals

Glucosamine Sulfate Capsules

Product Name
硫酸氨基葡萄糖胶囊
Approval Number
国药准字H20254467
Approval Date
Jun 3, 2025
NMPA

Empagliflozin Tablets

Product Name
恩格列净片
Approval Number
国药准字H20253500
Approval Date
Mar 4, 2025
NMPA

Rosuvastatin Calcium Tablets

Product Name
瑞舒伐他汀钙片
Approval Number
国药准字H20244465
Approval Date
Jul 16, 2024
NMPA

Vildagliptin Tablets

Product Name
维格列汀片
Approval Number
国药准字H20244268
Approval Date
Jun 28, 2024
NMPA

Oxymetazoline Hydrochloride Eye Drops

Product Name
风朗
Approval Number
国药准字H20030231
Approval Date
Jun 14, 2024
NMPA

Naphazoline Hydrochloride,Chlorphenamine Maleate and Vitamin B12 Eye Drops

Product Name
萘敏维滴眼液
Approval Number
国药准字H20045603
Approval Date
Jun 14, 2024
NMPA

Lafutidine Tablets

Product Name
拉呋替丁片
Approval Number
国药准字H20140112
Approval Date
Jun 14, 2024
NMPA

Oxymetazoline Hydrochloride Eye Drops

Product Name
风朗
Approval Number
国药准字H20030230
Approval Date
Jun 14, 2024
NMPA

Tobramycin Eye Drops

Product Name
妥布霉素滴眼液
Approval Number
国药准字H20055165
Approval Date
Jun 14, 2024
NMPA

Acarbose Tablets

Product Name
阿卡波糖片
Approval Number
国药准字H20243876
Approval Date
Jun 4, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.